Gut microbiome in chronic kidney disease

Area of Science:

• Microbiology
• Nephrology
• Gastroenterology

Background:

• The human intestine is a metabolic organ influenced by gut microbiota.
• Chronic kidney disease (CKD) is associated with significant alterations in the gut microbiome.
• These alterations contribute to the development of uraemic syndrome.

Purpose of the Study:

• To review the role of the gut microbiome in uraemic syndrome.
• To discuss gut microbiome-derived uraemic toxins and their impact on CKD.
• To explore potential therapeutic strategies for normalizing the gut microbiome in CKD.

Main Methods:

• Literature review focusing on the gut-kidney axis in CKD.
• Analysis of the contribution of specific gut microbiome-derived toxins (e.g., p-cresol sulfate, indoxyl sulfate, trimethylamine N-oxide) to CKD progression.
• Examination of the link between gut dysbiosis, inflammation, and cardiovascular disease in CKD patients.

Main Results:

• Altered gut microbiota in CKD patients produces key uraemic toxins.
• These toxins accelerate CKD progression, cardiovascular disease, and mortality.
• Gut-derived endotoxin translocation contributes to systemic inflammation in CKD.

Conclusions:

• The gut microbiome plays a critical role in CKD pathogenesis.
• Targeting the gut microbiome to restore symbiosis is a promising therapeutic strategy.
• Reducing uraemic toxin production and inflammation may improve outcomes for CKD patients.